Carsten Koall
Novavax (NASDAQ:NVAX) is scheduled to announce Q4 earnings results on Tuesday, February 28th, after market close.
The consensus EPS Estimate is -$1.05 (vs. -$11.18 last year) and the consensus Revenue Estimate is $383.14M (+72.4% Y/Y).
Over the last 1 year, NVAX has beaten EPS estimates 25% of the time and has beaten revenue estimates 25% of the time.
Over the last 3 months, EPS estimates have seen 2 upward revisions and 1 downward. Revenue estimates have seen 1 upward revision and 1 downward.
The company in early Nov. 2022 reported mixed results while providing FY 2023 revenue guidance below consensus.
NVAX has been hurt by dwindling COVID-19 cases which has affected demand for its protein-based vaccine.
NVAX had joined the COVID-19 vaccine race relatively much later than its peers, which had led to low adoption of its shot in terms of government orders.
In Q4, NVAX ended a vaccine deal with Gavi Alliance, citing a breach of contract.
Meanwhile, in late Dec. 2022, an Australian study showed that NVAX’s protein-based vaccine lagged in effectiveness as compared to mRNA-based shots.
In a positive for the company, the U.S. government earlier this month expanded its vaccine deal with NVAX after the Biden administration extended the country’s COVID-19 emergency till May.
